Oramed Q3 2022: loss per share $0.18; cash $160M; positive NASH and COVID-19 vaccine data

ORAMED PHARMACEUTICALS INC.

2022-Q3 EPS reported $0.72 revenue$2,022,000

Cash and investments approximately $160M as of September 30, 2022.
R&D expenses decreased 12% YoY to $5.3M; basic loss per share improved to $0.18 from $0.21.
Sales & marketing expense up 169% to $463K; G&A up 60% to $3.1M due to stock-based compensation.
Reported positive Phase 2 NASH data and positive initial Phase 1 oral COVID-19 vaccine results.
Phase 3 oral insulin (ORMD-0801) topline data expected in January 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORAMED PHARMACEUTICALS INC. reported the quarter ended September 30, 2022 results: EPS $0.18.

Period: the quarter ended September 30, 2022
EPS: $0.18
Result: reported results

Exact text from the filing

Basic and diluted loss per share of common stock for the three month period ended September 30, 2022 decreased by 14% to $0.18, compared to $0.21 for the three month period ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-071230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.